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journal.publications.chestneBACKGROUND: This phase 3 study further characterizes the efﬁcacy and safety of reslizumab (a
humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma
inadequately controlled by at least a medium-dose inhaled corticosteroid and with a blood
eosinophil count $ 400 cells/mL.
METHODS: Patients were randomized to receive reslizumab 0.3 or 3.0 mg/kg or placebo
administered once every 4 weeks for 16 weeks (total four doses). The primary end point was
change frombaseline in pre-bronchodilator FEV1 over 16weeks. Secondary end points included
FVC, forced expiratory ﬂow at 25% to 75% of FVC (FEF25%-75%), patient-reported control of
asthma symptoms, short-acting b-agonist (SABA) use, blood eosinophil levels, and safety.
RESULTS: Reslizumab signiﬁcantly improved FEV1 (difference vs placebo [reslizumab 0.3 and
3.0 mg/kg], 115 mL [95% CI, 16-215; P ¼ .0237] and 160 mL [95% CI, 60-259; P ¼ .0018]).
Clinically meaningful increases in FVC (130 mL) and FEF25%-75% (233 mL/s) were observed
with reslizumab 3.0 mg/kg. Reslizumab improved scores on the Asthma Control Questionnaire
(ACQ) and Asthma Quality of Life Questionnaire (AQLQ) vs placebo (greater effects seen
with 3.0 mg/kg; P < .05). The minimally important difference was reached for the AQLQ
(reslizumab 3.0 mg/kg) but not on the ACQ. Scores on the Asthma Symptom Utility Index and
SABA use were improved with reslizumab. The most common adverse events were worsening
of asthma, headache, and nasopharyngitis; most events were mild to moderate in severity.
CONCLUSIONS: Reslizumab improved lung function, asthma control and symptoms, and quality
of life. It was well tolerated in patients with inadequately controlled asthma (despite standard
therapy) and elevated blood eosinophil levels. Overall, the 3.0-mg/kg dose of reslizumab provided
greater improvements in asthma outcomes vs the 0.3-mg/kg dose, with comparable safety.
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Asthma is a heterogeneous disease, with many patients
experiencing persistent symptoms despite use of
recommended asthma therapies. Although numerous
factors may account for poor treatment responses,
underlying pathobiological differences are increasingly
recognized as playing a role.1 Patients with
inﬂammation-predominant asthma have an increased
risk of recurrent exacerbations and hospitalizations.2
This subgroup is characterized by eosinophilic
inﬁltration of airway mucosa, with an associated
increase in eosinophils in the blood, sputum, and BAL
ﬂuid.2,3 Eosinophils have been implicated in epithelial
dysfunction, airway remodeling, hyperresponsiveness,
and late-phase allergic response.4-6
Eosinophil activation and maintenance depend on
IL-5, an eosinophil viability-enhancing factor; inhibition
of IL-5–mediated signaling disrupts maturation and
survival of eosinophils.7,8 Clinical studies with anti-IL-5
therapies have demonstrated decreases in eosinophil
levels, as well as signiﬁcant improvements in many of
the clinically relevant parameters associated with
eosinophilic asthma such as reduction in exacerbation
frequency and improved symptom control.9-11
Reslizumab, a humanized anti-IL-5 monoclonal
(IgG4/k) antibody, binds to circulating IL-5 and
downregulates the IL-5 signaling pathway.8,12
In preclinical studies, reslizumab demonstrated high
binding afﬁnity for IL-5 and potently inhibited IL-5
activity in a lung eosinophilia model.12 These studiesand the Aspen Allergy Conference, Aspen, Colorado (July 19-23,
2015).
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790 Original Researchprovided the rationale for targeting IL-5 with reslizumab
in patients with asthma and elevated eosinophil levels.
Reslizumab met clinical proof-of-concept for lung
function improvement and asthma control in a
phase 2 study of asthma patients with sputum
eosinophilia ($ 3%).13 Assessment of sputum
eosinophilia is not practical for large-scale clinical trials
and most community health-care providers. Secondary
analysis of existing data sets suggested that a
blood eosinophil count $ 400 cells/mL was highly
speciﬁc for sputum eosinophils $ 3%14,15; this level
was subsequently used as a surrogate for sputum
eosinophilia in the reslizumab phase 3 asthma program
(BREATH). Additional analyses also support the
relationship between elevated blood eosinophil count
and sputum eosinophilia,16 including a meaningful
treatment effect being observed in a subset of patients
with a baseline eosinophil count $ 400 cells/mL in
a phase 3 trial.17 Overall, these ﬁndings support the
use of elevated blood eosinophil levels as an appropriate
biomarker for identifying a potential responder asthma
population for reslizumab.
The aim of the present phase 3 trial (part of the
BREATH program) was to further characterize the effect
of reslizumab on FEV1 at two different dose levels (0.3 and
3.0 mg/kg) in patients with persistent asthma and elevated
blood eosinophil counts ($ 400 cells/mL) whose symptoms
were inadequately controlled with inhaled corticosteroids
(ICS), with or without additional asthma controllers.Methods
Patients
Eligible patients were aged 12 to 75 years with inadequately controlled
asthma (Asthma Control Questionnaire [ACQ]-7 score $ 1.5), airway
reversibility ($ 12% to short-acting b-agonist [SABA]), were receiving
treatment with at least a medium-dose ICS (ﬂuticasone propionate
$ 440 mg/d or equivalent), and had at least one blood eosinophil
count $ 400 cells/mL during the screening period. Other permissible
baseline medications included long-acting bronchodilators,
leukotriene inhibitors, or cromolyn. The dose of permitted baselinemedications had to have been stable for 30 days prior to screening
and expected to remain unchanged throughout. Compliance to
current therapy was assessed at screening by interview and by asking
patients to demonstrate their inhaler technique. Patients who did not
use their inhaler correctly were shown the correct method and
allowed 2 weeks during the screening period to stabilize.
Maintenance oral corticosteroids were not allowed. There were no
FEV1 or asthma exacerbation inclusion requirements.
Key exclusion criteria are provided in e-Appendix 1. The study was
conducted in accordance with Good Clinical Practice guidelines, the
Declaration of Helsinki, and local regulatory requirements. Relevant
health authorities and local ethics committees or institutional review
boards approved the study protocols (e-Table 1); all patients
provided written informed consent.
Study Design and Treatments
This study was a randomized, double-blind, placebo-controlled,
parallel-group, ﬁxed-dosage, phase 3 trial conducted at 68 locations
globally.18 The study consisted of a 2- to 4-week screening period
and a 16-week double-blind treatment period, with a ﬁnal evaluation
4 weeks after the last infusion (end-of-treatment visit); after this
visit, patients could enroll in an optional open-label extension study
or return for a ﬁnal end-of-study visit. Eligible patients were[ 1 5 0 # 4 CHES T OC TO B E R 2 0 1 6 ]
randomized (1:1:1) to receive infusions of reslizumab 0.3 mg/kg,
reslizumab 3.0 mg/kg, or placebo administered once every 4 weeks
(total of 4 doses). Patients were stratiﬁed according to age group
(12-17 years or $ 18 years) and history of asthma exacerbations
within 12 months prior to screening (yes/no). Exacerbations were
deﬁned as one of the following: a reduction in FEV1 of $ 20%,
hospitalization due to asthma, emergency treatment of asthma,
or use of systemic corticosteroids for $ 3 days. Patients were to
refrain from using SABAs for 6 h prior to each study visit (including
screening). Patients taking long-acting b-agonists (LABAs) were
to withhold use for 12 h prior to each study visit.
Efﬁcacy Assessments and End Points
Efﬁcacy assessments included pre-bronchodilator spirometry (FEV1,
FVC, and forced expiratory ﬂow at 25% to 75% of FVC [FEF25%-
75%]), asthma symptoms (ACQ,
19 ACQ-6, ACQ-5) and Asthma
Symptom Utility Index [ASUI20]), Asthma Quality of Life
Questionnaire (AQLQ21), rescue inhaler use, and blood eosinophil
levels. Rescue inhaler use was assessed via patient recall of the
number of inhalations over the preceding 3 days. Given the limited
16-week duration of the study, it was not designed to assess asthma
exacerbations as an efﬁcacy end point.
Efﬁcacy end points were assessed at baseline and every 4 weeks thereafter
up to week 16 or at early withdrawal, except for AQLQ, which was ﬁrst
assessed at week 16. Safety and tolerability were evaluated according to
reported adverse events (AEs) coded by using the Medical Dictionary
for Regulatory Activities version 15.0, clinical laboratory test results,
vital signs, ECG ﬁndings, physical examination, use of concomitant
medication, and determination of antidrug antibodies (ADAs).journal.publications.chestnet.orgStatistical Analysis
The primary objective was to determine whether reslizumab 0.3 mg/kg
or 3.0 mg/kg improved FEV1 compared with placebo over 16 weeks in
patients with persistent asthma and elevated blood eosinophil levels.
The primary analysis was conducted in the full analysis set,
consisting of all randomized patients who received $ 1 dose of
study drug. Pulmonary function tests, ACQ, AQLQ, ASUI, and
SABA assessments were excluded from the full analysis set if they
were obtained at scheduled visits that were preceded by usage
(within 7 days) of a limited subset of medications that could
signiﬁcantly confound interpretation (including oral or systemic
corticosteroids, or the addition of a LABA or a long-acting
muscarinic antagonist if not taken at baseline) and in violation of
the protocol. Assessment of ACQ-6 and ACQ-5 was not predeﬁned.
The safety analysis set included patients receiving $ 1 dose of study
drug.
FEV1 was analyzed by using a mixed effect model for repeated
measures, with ﬁxed effects (ie, treatment, stratiﬁcation factors, sex,
visit, interaction of treatment and visit), covariates (ie, height,
baseline value), and patient as the random effect. More details on
the primary end point analysis are provided in e-Appendix 2.
For secondary efﬁcacy end points, a stratiﬁed Cochran-Mantel-
Haenszel test was used to analyze the proportion of patients
achieving a minimally important difference of $ 0.5-point
reduction in ACQ or $ 0.5-point improvement in AQLQ scores.
The mixed effect model for repeated measures was used for
secondary pulmonary function measures, ASUI scores, SABA
therapy, and blood eosinophil levels. No adjustment for multiplicity
was applied.Results
Patients
Of 1,025 screened patients, 315 were randomly assigned
to treatment (Fig 1). Of the 710 patients not enrolled,
626 (88%) did not meet inclusion criteria, the most
common reason being baseline blood eosinophil
levels < 400 cells/mL. Of the enrolled patients, 265 (84%)
completed the study. The most common reason
for study discontinuation was occurrence of AEs.
The efﬁcacy analysis set (full analysis set) and safety
analysis set (patients receiving $ 1 dose of study drug)
included 311 (99%) patients. At the end of treatment,
271 patients (179 reslizumab-treated, 92 receiving
placebo) elected to roll over into an open-label extension
study of the 3.0-mg/kg dose.22
Patient demographic and baseline disease characteristics
were similar between groups (Table 1). The majority of
patients were taking an ICS plus a LABA; mean ACQ
scores were indicative of a population with inadequately
controlled asthma.Efﬁcacy Outcomes
Overall change in FEV1 over 16 weeks improved
signiﬁcantly with reslizumab 0.3 mg/kg (115 mL;P¼ .0237) and 3.0 mg/kg (160 mL; P¼ .0018) compared
with placebo (Fig 2, Table 2). FEV1 improved as early
as 4 weeks with reslizumab 3.0 mg/kg vs placebo
(treatment difference, 153 mL); this improvement
was maintained for the duration of the study. Baseline
eosinophil levels $ 400 cells/mL (< 500 [but $ 400];
and $ 500 cells/mL) did not consistently inﬂuence the
magnitude of improvements in FEV1; the exception was a
trend toward a larger treatment effect (compared with the
overall effect) for the 3.0-mg/kg dose beginning at an
eosinophil count$ 700 cells/mL (e-Fig 1). In addition,
short-term variability in blood eosinophil counts
(ie, primary inclusion of $ 1 blood eosinophil
count $ 400 cells/mL during screening vs $ 400 cells/
mL at all assessments including baseline) had no notable
effect on the primary efﬁcacy outcome. However, it is
important to note that the number of patients in the
sensitivity analyses was low (difference from placebo,
135 mL [$ 1 screen eosinophil < 400 cells/mL]
vs 155 mL [all $ 400 cells/mL]; 3.0 mg/kg reslizumab).
Reslizumab 3.0 mg/kg produced substantial
improvements in FVC (treatment difference, 130 mL)
and FEF25%-75% (treatment difference, 233 mL/s)
vs placebo over the 16-week treatment period (e-Fig 2,
Table 2); negligible or no improvements in FVC and791
Reason for withdrawal from study
(treatment and follow-up)
Adverse event (n = 9 [9%])
Protocol violation (n = 4 [4%])
Lack of efficacy (n = 2 [2%])
Consent withdrawn (n = 2 [2%])
Lost to follow-up (n = 2 [2%])
Other (n = 1 [< 1%]): transferred to
open-label extension study
Placebo (n = 105)
Evaluable for safety (n = 105)
Evaluable for efficacy (n = 105)
Evaluable for PK (n = 105)
Reason for withdrawal from study
(treatment and follow-up)
Lack of efficacy (n = 3 [3%])
Protocol violation (n = 3 [3%])
Lost to follow-up (n = 3 [3%])
Consent withdrawn (n = 1 [< 1%])
Adverse event (n = 1 [< 1%])
Other (n = 1 [< 1%]): patient did not
feel improvement
Reason for withdrawal from study
(treatment and follow-up)
Adverse event (n = 7 [7%])
Consent withdrawn (n = 4 [4%])
Protocol violation (n = 2 [2%])
Lost to follow-up (n = 1 [< 1%])
Lack of efficacy (n = 1 [< 1%])
Other (n = 3 [< 3%]): patient was
discontinued; randomization error;
transferred to open-label
extension study
Screened but not
enrolled/randomized (n = 710)
Inclusion criteria not met (n = 626)
Consent withdrawn (n = 22)
Exclusion criteria met (n = 18)
Adverse event (n = 9)
Lost to follow-up (n = 7)
Other (n = 28)
Patients
withdrawn
(n = 20 [19%])
Patients
completed
(n = 85 [81%])
Patients
withdrawn
(n = 12 [12%])
Patients
completed
(n = 92 [88%])
Patients
withdrawn
(n = 18 [17%])
Patients enrolled/
randomizeda
(n = 315)
Patients screened
(N = 1,025)
Patients
completed
(n = 88 [83%])
Reslizumab 3.0 mg/kg (n = 106)
Evaluable for safety (n = 103)
Evaluable for efficacy (n = 103)
Evaluable for PK (n = 103)
Reslizumab 0.3 mg/kg (n = 104)
Evaluable for safety (n = 103)
Evaluable for efficacy (n = 103)
Evaluable for PK (n = 103)
Figure 1 – Patient disposition. aFollowing participation in this study, 271 patients (92 receiving placebo, 179 receiving reslizumab) were enrolled in an
open-label extension study to obtain long-term safety and efﬁcacy data for reslizumab. PK ¼ pharmacokinetics.FEF25%-75% were observed for reslizumab 0.3 mg/kg.
Reslizumab 0.3 mg/kg and 3.0 mg/kg improved rescue
inhaler use (e-Fig 3, Table 2), ACQ, and asthma
symptoms (e-Fig 4, Table 2); overall improvements in
ACQ were numerically greater for the 3.0-mg/kg dose.
Similar results as those observed for ACQ were seen
for ACQ-5 and ACQ-6 (reslizumab 3.0 mg/kg).
Improvements in AQLQ scores were observed for
reslizumab 3.0 mg/kg. Decreases in blood eosinophil
levels were observed for both reslizumab doses and
were greatest for reslizumab 3.0 mg/kg (Fig 3, Table 2).
Sensitivity analyses without data exclusion
for concomitant medication violations were consistent
with results of the primary analysis (e-Table 2).
The proportion of patients with an minimally
important difference of $ 0.5 improvement from
baseline to end point in AQLQ total score was
higher with reslizumab 3.0 mg/kg vs placebo (64%792 Original Researchvs 48%, respectively; P ¼ .0189) and higher with
reslizumab 0.3 mg/kg (59%; P ¼ not signiﬁcant).
For ACQ, a similar proportion of patients in the
reslizumab groups and placebo group achieved a
0.5-point reduction from their baseline score to end
point (P ¼ not signiﬁcant).
Safety and Tolerability
Treatment with reslizumab at both study doses was
generally well tolerated. A lower proportion of patients
receiving reslizumab 0.3 mg/kg (n ¼ 59 [57%]) and
3.0 mg/kg (n ¼ 61 [59%]) experienced$ 1 AE compared
with placebo (n ¼ 66 [63%]) (Table 3). Treatment-related
AEs were reported in eight (8%) patients in the placebo
group, 12 (12%) in the 3.0-mg/kg reslizumab group, and
six (6%) in the 0.3-mg/kg reslizumab group; the majority
of AEs were mild to moderate in severity and were
self-limiting. The most common AEs were worsening of[ 1 5 0 # 4 CHES T OC TO B E R 2 0 1 6 ]
TABLE 1 ] Patient Demographic and Baseline Disease Characteristics (Randomized Patients)
Characteristic
Placebo
(n ¼ 105)
Reslizumab
0.3 mg/kg
(n ¼ 104)
Reslizumab
3.0 mg/kg
(n ¼ 106)
Demographics
Mean age, y 44.2 44.5 43.0
Adolescents (aged 12-17 y), No. (%) 5 (5) 5 (5) 5 (5)
Adults (aged $ 18 y), No. (%) 100 (95) 99 (95) 101 (95)
Sex, %
Female 59 57 58
Male 41 43 42
Race, %
White 81 77 85
Black 7 6 5
Asian 0 2 2
Othera 12 15 8
Ethnicity, %
Non-Hispanic, non-Latino 70 70 71
Hispanic or Latino 28 28 29
BMI, mean, kg/m2 27.7 27.6 27.4
Disease characteristics
Mean time since diagnosis, y 20.7 20.0 20.4
Exacerbation within 12 mo, % 54 56 57
ACQ score, mean 2.471 2.481 2.590
AQLQ score, mean 4.374 4.501 4.175
ASUI score, mean 0.674 0.675 0.655
Airway reversibility, mean, % 25.4 24.2 26.2
FEV1, mean, L 2.222 2.157 2.192
FEV1, mean, % predicted 71.1 68.8 70.4
Rescue use: mean No. of inhalations/d 2.3 1.9 2.2
Blood eosinophils, mean (range), cells/mLb 601 (100-3,700) 648 (100-3,700) 592 (100-2,300)
Treated with LABA, % 80 78 75
Total daily dose of ICS, mean, mgc 756.7 756.3 813.5
ACQ ¼ Asthma Control Questionnaire; AQLQ ¼ Asthma Quality of Life Questionnaire; ASUI ¼ Asthma Symptom Utility Index; ICS ¼ inhaled cortico-
steroids; LABA ¼ long-acting b-agonist.
aIncludes American Indian, Alaska Native, Paciﬁc Islander, and other.
bPatients had at least one blood eosinophil level $ 400 cells/mL during the 2- to 4-wk screening period.
cFluticasone propionate equivalent.asthma, headache, nasopharyngitis, upper respiratory tract
infection, and sinusitis.
Five patients experienced serious AEs, including
acute myocardial infarction in the placebo group
(n ¼ 1), and asthma exacerbation (n ¼ 2), sinusitis
(n ¼ 1), and pneumonia, road trafﬁc accident, rib
fracture, and asthma exacerbation (n ¼ 1) in the
reslizumab 3.0-mg/kg group. No serious AEs were
considered related to the study drug. Ten (10%) patients
in the placebo group, one (< 1%) in the 0.3-mg/kg
reslizumab group, and six (6%) in the 3.0-mg/kgjournal.publications.chestnet.orgreslizumab group withdrew from the study due to AEs
(Table 3), most commonly because of an asthma
exacerbation. Of note, a requirement for systemic
corticosteroid therapy for asthma worsening required
withdrawal according to the study protocol. One patient
was withdrawn from the reslizumab 3.0-mg/kg group for
mild myalgia that was assessed as treatment-related by
the investigator. No deaths occurred during the study.
ADA responses were detected in 12% and 11% of
patients in the reslizumab 0.3-mg/kg and 3.0-mg/kg
groups, respectively. Eight percent of patients who were793
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Figure 2 – Change in FEV1 over 16 wks. *P# .05 vs placebo. Only wk 16
was controlled for type I error; all other P values were not adjusted to
control for multiplicity. LS ¼ least squares.subsequently randomized to receive reslizumab had a
positive ADA response at baseline (ie, before exposure
to the drug). This ﬁnding is not unexpected in an assay
that is designed to be highly sensitive. Positive ADA
responses were of low titer, and the majority of patients
were positive at only one time point over the 16-weekTABLE 2 ] Efﬁcacy End Points Over 16 Weeks (Full Analysi
Variable
Placebo
(n ¼ 105)
FEV1, L (primary end point)
No. 103
LS mean  SE 0.126  0.0549
D (95% CI)a
P value
FVC, L
No. 103
LS mean  SE 0.172  0.0614
D (95% CI)a
P value
FEF25%-75%, L/s
No. 103
LS mean  SE –0.145  0.1342
D (95% CI)a
P value
SABA use, puffs/d
No. 102
LS mean  SE –0.3  0.28
D (95% CI)a
P value
794 Original Researchtreatment period. The AE proﬁle of ADA-positive
patients was similar to that observed in the overall
population. The overall pattern of blood eosinophil
suppression by reslizumab in treatment-emergent
ADA-positive patients, as a group, was similar to that in
ADA-negative patients, indicating that any ADAs, if
present, were not neutralizing.
Discussion
In the present study, the choice of a blood eosinophil
threshold of $ 400 cells/mL was used to select patients
with a high likelihood of having active eosinophilic
airway inﬂammation and therefore most likely to beneﬁt
from reslizumab. The randomized patient population
was consistent with the intended inadequately controlled
asthma population based on average ACQ score, AQLQ
score, and baseline symptoms; 78% of patients were
using a LABA in addition to ICS. Treatment with
reslizumab 0.3 mg/kg and 3.0 mg/kg signiﬁcantly
improved pre-bronchodilator FEV1 over 16 weeks
vs placebo. Improvements in FEV1 were larger
for reslizumab 3.0 mg/kg compared with reslizumab
0.3 mg/kg and were observed after the ﬁrst dose ofs Set)
Reslizumab
0.3 mg/kg
(n ¼ 104)
Reslizumab
3.0 mg/kg
(n ¼ 106)
101 102
0.242  0.0556 0.286  0.0548
0.115 (0.016 to 0.215) 0.160 (0.060 to 0.259)
.0237 .0018
101 102
0.220  0.0623 0.301  0.0613
0.048 (–0.058 to 0.155) 0.130 (0.023 to 0.237)
.3731b .0174b
101 102
–0.114  0.1361 0.089  0.1342
0.030 (–0.209 to 0.270) 0.233 (–0.005 to 0.472)
.8020b .0552b
101 102
–1.0  0.28 –0.9  0.27
–0.648 (–1.152 to –0.144) –0.624 (–1.126 to –0.121)
.0119b .0151b
(Continued)
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TABLE 2 ] (Continued)
Variable
Placebo
(n ¼ 105)
Reslizumab
0.3 mg/kg
(n ¼ 104)
Reslizumab
3.0 mg/kg
(n ¼ 106)
ACQ
No. 103 101 101
LS mean  SE –0.494  0.1231 –0.732  0.1250 –0.853  0.1233
D (95% CI)a –0.238 (–0.456 to –0.019) –0.359 (–0.577 to –0.140)
P value .0329b .0014b
ACQ-5
No. 103 101 101
LS mean –0.568 –0.788 –0.917
D (95% CI)a –0.220 (–4.60 to 0.020) –0.349 (–0.590 to –0.109)
P value .0726 .0045
ACQ-6
No. 103 101 101
LS mean –0.514 –0.751 –0.838
D (95% CI)a –0.236 (–0.465 to –0.007) –0.323 (–0.553 to –0.094)
P value .043 .0058
AQLQc
No. 101 96 99
LS mean  SE 0.779  0.1817 1.057  0.1881 1.138  0.1829
D (95% CI)a 0.278 (–0.036 to 0.591) 0.359 (0.047 to 0.670)
P value .0822b .0241b
ASUI
No. 103 101 101
LS mean  SE 0.082  0.0218 0.132  0.0221 0.129  0.0218
D (95% CI)a 0.051 (0.012 to 0.089) 0.047 (0.009 to 0.085)
P value .0094b .0160b
Blood eosinophil level, cells/mL
No. 103 101 102
LS mean  SE –35  27.1 –358  27.7 –529  27.0
D (95% CI)a –323 (–370 to –275) –494 (–542 to –447)
P value .0000b .0000b
FEF25%-75% ¼ forced expiratory ﬂow at 25% to 75% of FVC; LS ¼ least squares; SABA ¼ short-acting b-agonist. See Table 1 legend for expansion of other
abbreviations.
aTreatment difference (reslizumab – placebo).
bP values are not adjusted to control for multiplicity.
cAQLQ was only assessed once during the study (at wk 16 or early withdrawal).treatment. Furthermore, variations in baseline
eosinophil levels of > 500 and $ 800 cells/mL did not
meaningfully inﬂuence FEV1 outputs with the 3.0-mg/kg
dose of reslizumab. Overall improvements in FVC
and FEF25%-75% were observed only for reslizumab
3.0 mg/kg, suggesting that patients may require this
higher exposure to the drug to derive meaningful
improvements in these lung function parameters.
The increase in FVC observed with reslizumab
3.0 mg/kg, indicative of a reduction in air trapping
and recruitment of peripheral airways, is particularlyjournal.publications.chestnet.orginteresting because it suggests that a higher dose of
reslizumab may be needed to treat active eosinophilic
inﬂammation in the peripheral airways.
Both reslizumab doses improved patient-reported
asthma control vs placebo as assessed by using ACQ and
ASUI scores. The magnitude of improvement in ACQ-7
and AQLQ was larger for reslizumab 3.0 mg/kg than for
reslizumab 0.3 mg/kg. Improvements in ACQ-6
(no lung function domain) were comparable with ACQ-
7 results, suggesting that the observed improvements795
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Figure 3 – Change in blood eosinophil levels over 16 wks.in asthma control were not driven by improvement in
FEV1 alone. Decreases in rescue inhaler use were also
observed for both reslizumab doses vs placebo. Overall
reductions in blood eosinophil levels were greater
with reslizumab vs placebo, with the greatest decreases
observed with the 3.0-mg/kg dose. At least one-half of
patients achieved a $ 0.5-point improvement in AQLQ
and ACQ score with both doses of reslizumab; the
differences for ACQ were not statistically different.
However, a recent systematic review and meta-analysis
reported by Bateman et al23 suggests that the establishedTABLE 3 ] Summary of AEs (Safety Population)
AE
Any AEs
Treatment-related AEs
Serious AEs
Discontinuations due to AEs
AEs in > 2% of patients in any reslizumab group (preferred term)
Asthma worsening
Headache
Nasopharyngitis
Upper respiratory tract infection
Sinusitis
Urinary tract infection
Dyspnea
Bronchitis
Nausea and vomitinga
Allergic rhinitis
Pharyngitis
Acute sinusitis
Data are presented as No. (%). AE ¼ adverse event.
aHigh-level term used to reﬂect concurrence of these related events in the sam
796 Original Researchwithin-patient minimally important difference for
the ACQ and AQLQ is not achievable as a group-wise
efﬁcacy threshold between treatment arms in clinical
studies in which controllers are added to ICS treatment.
Early clinical studies investigating anti-IL-5 antibodies as
therapy in unselected patients with asthma (ie, irrespective
of eosinophil levels) have shown limited clinical
efﬁcacy.24-26 In a subsequent randomized study in
patients with inadequately controlled asthma and sputum
eosinophilia ($ 3%), treatment with reslizumab 3.0 mg/kg
improved FEV1, asthma control, and the number of
exacerbations compared with placebo.13 The clinical
outcomes observed with reslizumab 3.0 mg/kg in the
present trial support the efﬁcacy of this dose in asthma
patientswith elevatedbloodeosinophil levels, particularly in
terms of early improvement in airway function (including
indices of air trapping and small airway function) vs the 0.3-
mg/kg dose. A companion phase 3 study further conﬁrmed
the utility of a blood eosinophil level$ 400 cells/mL for
selecting reslizumab-responsive patients.17
As part of the BREATH program, Castro et al27 recently
demonstrated a signiﬁcant reduction in asthma
exacerbations and improvements in lung function,
symptoms, and disease-speciﬁc quality of life with
reslizumab 3.0 mg/kg vs placebo; the investigators used
duplicate randomized, placebo-controlled phase 3 trialsPlacebo
(n ¼ 105)
Reslizumab
0.3 mg/kg
(n ¼ 103)
Reslizumab
3.0 mg/kg
(n ¼ 103)
66 (63) 59 (57) 61 (59)
8 (8) 6 (6) 12 (12)
1 (< 1) 0 4 (4)
10 (10) 1 (< 1) 6 (6)
20 (19) 6 (6) 16 (16)
6 (6) 8 (8) 11 (11)
4 (4) 6 (6) 6 (6)
3 (3) 3 (3) 5 (5)
3 (3) 3 (3) 4 (4)
3 (3) 1 (< 1) 4 (4)
1 (< 1) 1 (< 1) 4 (4)
5 (5) 5 (5) 2 (2)
0 4 (4) 2 (2)
4 (4) 4 (4) 1 (< 1)
3 (3) 3 (3) 1 (< 1)
2 (2) 3 (3) 1 (< 1)
e patient.
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of patients with inadequately controlled asthma, elevated
blood eosinophil levels ($ 400 cells/mL), and history
of asthma exacerbation.
Another IL-5 inhibitor, mepolizumab, was studied in
patients with asthma inadequately controlled with
high-dose ICS plus an additional controller and who had
experienced $ 2 asthma exacerbation during the past
year. “Probable” eosinophilic asthma included patients
with blood eosinophil counts $ 150 cells/mL or with a
history of eosinophil counts $ 300 cells/mL10 or with
other surrogate markers of airway eosinophilia.11
The Dose Ranging Efﬁcacy and Safety with
Mepolizumab (DREAM) study found no signiﬁcant
differences compared with placebo in any of the
secondary end points tested, including FEV1 and ACQ.
The subsequent Mepolizumab as Adjunctive Therapy in.
Patients with Severe Asthma (MENSA) study, however,
did ﬁnd impacts on these end points, with larger
improvements observed in patients with higher baseline
eosinophil counts.10 Thus, the consistent clinical
improvements observed with reslizumab across multiple
measures of asthma control and lung function are
probably due to inclusion of patients who are more
likely to have active eosinophilic airway inﬂammation
(based on higher screening blood eosinophil count),
consistent therapeutic exposures afforded by thejournal.publications.chestnet.orgweight-based dosing regimen, and to the high afﬁnity
of reslizumab for IL-5.8
Reslizumab was generally well tolerated in the present
study, with a safety proﬁle commensurate with
previously reported trials of reslizumab.13,26,27 Most
AEs were mild or moderate in severity and not
considered treatment related, and AEs and withdrawals
due to AEs were infrequent, the nature and pattern
of which raise no speciﬁc concerns. Importantly, safety
and tolerability were similar between the 0.3-mg/kg and
3.0-mg/kg doses, indicating that the more pronounced
clinical beneﬁt achieved with reslizumab 3.0 mg/kg was
not associated with decreased safety or tolerability.
Conclusions
IV reslizumab 3.0 mg/kg provided improvements in
lung function, asthma symptoms, and quality of life for
patients with inadequately controlled asthma and
elevated blood eosinophil levels ($ 400 cells/mL) that
were generally greater than those provided with the 0.3-
mg/kg dose. These efﬁcacy ﬁndings are consistent with
results from other reslizumab trials and, combined with
the favorable safety proﬁle observed, support the use of
reslizumab 3.0 mg/kg in patients with asthma and
elevated blood eosinophil counts uncontrolled with an
ICS-based regimen.Acknowledgments
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